---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-035179"
form_type: "8-K"
ticker: "XWEL"
cik: "0001410428"
company_name: "XWELL, Inc."
filed_at: "2025-04-15T23:59:59+00:00"
generated_at: "2026-05-23T14:25:32.212288+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# XWELL reports FY 2024 revenue $33.9M (+13% YoY), net loss narrows to $16.9M

## Summary
- Revenue $33.9M (+13% YoY); gross margin rose to 26.3% from 12.2%.
- Net loss attributable to XWELL narrowed to $16.9M from $27.7M in 2023.
- CDC extended Traveler-based Genomic Surveillance Program for 3 years; base value $53.7M, ceiling $85.7M.
- Closed $4M private placement in Jan 2025; plans to acquire medical spas in select metros in 2025.
- Cash & equivalents $4.6M, marketable securities $7.3M, no long-term debt.

## SEC filing metadata
- accession: 0001104659-25-035179
- form_type: 8-K
- ticker: XWEL
- cik: 0001410428
- company_name: XWELL, Inc.
- filed_at: 2025-04-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1410428/000110465925035179/0001104659-25-035179-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1410428/000110465925035179/tm2512312d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-035179
- JSON: https://secwatch.observer/filing/0001104659-25-035179.json
- Plain text: https://secwatch.observer/filing/0001104659-25-035179.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.